TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
7.50
-0.27 (-3.47%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close7.77
Open7.66
Bid6.96 x 3100
Ask7.00 x 3200
Day's Range7.41 - 7.88
52 Week Range6.07 - 24.47
Volume20,151,619
Avg. Volume20,505,103
Market Cap8.665B
Beta (3Y Monthly)2.42
PE Ratio (TTM)N/A
EPS (TTM)-3.79
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-27
1y Target Est9.26
Trade prices are not sourced from all markets
  • Barrons.com

    Health-Care Stocks Are Getting Back on Their Feet

    Health-care stocks were the best-performing group in the S&P 500 last week, after a dismal performance this year. And their recovery might just be starting.

  • Barrons.com

    It’s Crunch Time for an Opioid Settlement Before Key Trial Starts

    Friday is the last business day before the start of a key trial in the sprawling opioid litigation, and investors are watching to see if the sides reach a settlement before the jury sits down on Monday morning.

  • Bloomberg

    Settling Opioid Suits Probably Won’t End the Crisis

    (Bloomberg Opinion) -- Imagine you’re the chief executive officer of a large pharmaceutical corporation with an important drug that’s under attack. More than 2,500 lawsuits have been filed against your company. The plaintiffs aren’t individuals, though, they’re governments — counties, cities and states. And some of the biggest names in the plaintiffs’ bar have agreed to represent these entities, lawyers like Joe Rice, whose firm was said to have earned $1 billion for helping to bring the tobacco companies to heel in the 1990s.You know you’ve got some incriminating-sounding documents in your corporate files — what company doesn’t? — but you also know that the Food and Drug Administration approved your drug. Patients crushed it and snorted it — something that was never intended. And you’re convinced that the plaintiffs are pushing the envelope with the public nuisance laws they are relying on to bring these cases. Yes, your company will probably lose at trial, but you think you have a good chance to win on appeal.Then you look at the army arrayed against you, and it hits you: You’re never going to be able to litigate your way out of this. It’s not just that there are 2,500 lawsuits or that they are being brought by governments. It is what that represents. Government exists to serve the interests of the people, and the people are saying that your company participated in something that inflicted tremendous damage on the country. Hundreds of thousands of people have died. And your company needs to be punished.At this point, you pick up the phone, call your opponents and say, “How much do we need to pay to settle this?”I am obviously not privy to the thinking of the CEOs of the various companies facing opioid lawsuits. But given the news of the last few days, I imagine that their thought process was not too far from what I just described. On Tuesday, the Wall Street Journal reported that three of the distributors being sued — McKesson Corp., Cardinal Health Inc., and AmerisourceBergen Corp. — have offered to pay $18 billion over 18 years to settle their cases. This news leaked less than a week before the start of a big opioid trial in Cleveland, in which the three companies are among the defendants.The next day, Bloomberg News reported that Johnson & Johnson was offering $4 billion to end the litigation, and Teva Pharmaceutical Industries Inc. was proposing to give away $15 billion worth of generic drugs to be freed of the lawsuits. On Thursday, the New York Times reported that the five companies and the states had agreed on the outlines of a settlement that would cost the companies $50 billion.And of course, Purdue Pharma Inc. had already waved the white flag, with a bankruptcy filing last month intended to end the lawsuits by essentially turning the company’s assets over to a trust that would be controlled by the plaintiffs.It is too early to know whether any of these settlement offers will stick. Although the federal judge presiding over the Cleveland trial, Dan Aaron Polster, has asked the CEOs of the three distributors plus Teva to appear Friday to discuss the settlement talks, I’m told that the trial is still likely to begin on Monday, as scheduled.Any settlement will also need approval from the cities and counties that have filed suits. They are deeply suspicious of any deal the states might cut because they remember the outcome of the tobacco litigation. In 1998, the tobacco companies agreed to pay $246 billion over 25 years to the states, but little of that money trickled down to cities and counties. Indeed, a minuscule amount went to anti-tobacco efforts; most of the money is now used to fill state budget gaps.Still, whether it happens next week or next year, the opioid litigation will almost surely end with the companies being sued spending billions to settle it. The stock market practically demands it: Share prices of all the companies that have made settlement offers in recent days have jumped. And continuing litigation drains and distracts a company.Here’s the problem, though. Whenever plaintiffs’ lawyers argue that companies have done bad things and need to pay up, they justify the demand for money by saying it will be used to solve the problem. But will it? In this case, I have my doubts.In an opioid case in Oklahoma a few months ago, a judge ruled that Johnson & Johnson should pay $572 million (later reduced by $107 million), which he calculated would cover opioid abatement services in Oklahoma for just one year. So point one: Ending the crisis will require more money than even Big Pharma can provide.Second, just throwing money at the problem is not going to solve it. States and cities will most likely take different approaches. Some will be better than others. But there is no clear plan coming from the federal government — or anywhere else — about what steps are needed to end the crisis. Until there is, more money is likely to be wasted than not.Third, chances are good that the settlement money will be used for things that have nothing to do with opioids. Again, tobacco in instructive: Settlement money was supposed to be earmarked for tobacco control programs, but in most states the politicians couldn’t resist grabbing it for other purposes.Earlier this summer, during a court hearing, Judge Polster said that “developing solutions to combat a social crisis such as the opioid epidemic should not be the task of our judicial branch.” It was the job, he said, of the executive and legislative branches.He’s right. But that’s just not the American way. In the U.S., when there is a problem with a product, our first instinct is to sue the corporation that made it. When the litigation is settled, money is transferred from shareholders to plaintiffs (and their lawyers). It may be a satisfying resolution, but it rarely solves the problem. To reference tobacco one more time, two decades after the tobacco settlement, 480,000 Americans still die from smoking each year.I suspect the same will be true of the opioid crisis. The companies will settle, the lawyers will pocket millions and the states will get the rest. And the crisis will continue.I’ve said it before, and I’ll no doubt say it again: There’s got to be a better way.To contact the author of this story: Joe Nocera at jnocera3@bloomberg.netTo contact the editor responsible for this story: Daniel Niemi at dniemi1@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Joe Nocera is a Bloomberg Opinion columnist covering business. He has written business columns for Esquire, GQ and the New York Times, and is the former editorial director of Fortune. His latest project is the Bloomberg-Wondery podcast "The Shrink Next Door."For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • Reuters

    UPDATE 1-Judge summons drug company CEOs to discuss opioid settlement - source

    The chief executives of the three largest U.S. drug distributors and a drugmaker have been summoned to appear before a federal judge to discuss a proposal to resolve thousands of lawsuits alleging they fueled the U.S. opioid crisis, a person familiar with the matter said on Thursday. The order by U.S. District Judge Dan Polster in Cleveland, Ohio, came as distributors McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp and Israel-based drugmaker Teva Pharmaceutical Industries Ltd moved to reach a deal ahead of a trial before Polster that begins on Monday. All of those companies except J&J are set to be defendants in the trial before Polster, who oversees the bulk of the litigation.

  • Drug Suppliers Reportedly Near $50 Billion Deal In Opioid Lawsuits
    Investor's Business Daily

    Drug Suppliers Reportedly Near $50 Billion Deal In Opioid Lawsuits

    The biggest drug distributors, plus Johnson & Johnson and Teva Pharmaceutical, are reportedly on the brink of a $50 billion deal to settle thousands of cases related to the opioid epidemic.

  • Teva Breaks Out Amid Hopes of Global Opioid Settlement
    Investopedia

    Teva Breaks Out Amid Hopes of Global Opioid Settlement

    Teva shares jumped higher after Gabelli upgraded the stock, saying that $15 billion in drug giveaways could have a limited EBITDA impact.

  • Teva's UK arm recalls some batches of Ranitidine: Medicines watchdog
    Reuters

    Teva's UK arm recalls some batches of Ranitidine: Medicines watchdog

    Teva, the world's largest generic drugmaker, is recalling all unexpired stock of Ranitidine Effervescent Tablets in 150 micrograms and 300 micrograms dosages, the Medicines and Healthcare products Regulatory Agency (MHRA) said https://www.gov.uk/government/news/ranitidine-mhra-drug-alert-issued-for-teva-uk-recall.

  • Reuters

    Teva's UK arm recalls some batches of Ranitidine - Medicines watchdog

    Teva Pharmaceutical's UK unit has recalled some batches of heartburn medicine Ranitidine, Britain's medicines watchdog said on Thursday, making it the latest drugmaker to pull the product. Teva, the world's largest generic drugmaker, is recalling all unexpired stock of Ranitidine Effervescent Tablets in 150 micrograms and 300 micrograms dosages, the Medicines and Healthcare products Regulatory Agency (MHRA) said https://www.gov.uk/government/news/ranitidine-mhra-drug-alert-issued-for-teva-uk-recall. Teva did not immediately respond to a request for comment.

  • Barrons.com

    Teva Stock Is Jumping After Reports It May Trade Generic Drugs for an Opioid Settlement

    Shares of Teva Pharmaceutical Industries were up nearly 3% in premarket trading on Thursday amid news that the company has a deal to settle many of the opioid cases against it.

  • Market Exclusive

    Market Morning: Chinese Aircraft Carriers, DUP Sours on Brexit Deal, Big Opioid Settlement

    Chinese Aircraft Carrier Factory Revealed This will probably annoy the Trump Administration. Reuters reports exclusively that high-resolution satellite images show that China is progressing in the construction of a full sized aircraft carrier and should be the first of several large vessels produced. The site is called the Jinagnan shipyard and the images were taken […]The post Market Morning: Chinese Aircraft Carriers, DUP Sours on Brexit Deal, Big Opioid Settlement appeared first on Market Exclusive.

  • Broad opioid settlement talks heat up as federal trial looms
    MarketWatch

    Broad opioid settlement talks heat up as federal trial looms

    Efforts to settle thousands of lawsuits related to the nation’s opioid epidemic intensified Wednesday ahead of the scheduled start of arguments in the first federal trial over the crisis.

  • Reuters

    UPDATE 2-Drug firms offer to settle U.S. opioid suits with $50 bln package -sources

    Five drugmakers and distributors are offering $22 billion in cash as well as drugs and services they value at $28 billion to resolve lawsuits alleging the industry fuelled the U.S. opioid crisis, two sources familiar with the matter said on Wednesday. The drug industry faces roughly 2,600 lawsuits brought by state and local governments, hospitals and other entities seeking to hold drugmakers and distributors responsible for the toll of opioid abuse. Local governments seek funds to cover costs of services in their communities.

  • Drug firms offer to settle U.S. opioid suits with $50 billion package: sources
    Reuters

    Drug firms offer to settle U.S. opioid suits with $50 billion package: sources

    The drug industry faces roughly 2,600 lawsuits brought by state and local governments, hospitals and other entities seeking to hold drugmakers and distributors responsible for the toll of opioid abuse. Local governments seek funds to cover costs of services in their communities. Distributors McKesson Corp , AmerisourceBergen Corp and Cardinal Health have offered to pay $18 billion in cash over 18 years, while drugmaker Johnson & Johnson would pay $4 billion in cash, two people familiar with the matter told Reuters.

  • Benzinga

    Opioid Drug Companies Rally On Hopes of Broader Settlement

    Shares of companies embroiled in the U.S. opioid crisis were trading sharply higher Wednesday following a Tuesday  Wall Street Journal report that said three opioid drug distributors are in talks with ...

  • J&J Makes $4 Billion Opioid Offer as Distributors Seek Deal
    Bloomberg

    J&J Makes $4 Billion Opioid Offer as Distributors Seek Deal

    (Bloomberg) -- Johnson & Johnson has offered to pay $4 billion to settle all claims accusing the company of helping fuel the U.S. opioid epidemic, as part of a potentially larger deal involving drugmakers and distributors that could top $20 billion.J&J’s overture came on the heels of a proposal by distributors McKesson Corp., Cardinal Health Inc. and AmerisourceBergen Corp. to pay $18 billion to wipe out all opioid suits against those companies, according to people familiar with the proposal. The Wall Street Journal first reported the distributors’ offer Tuesday. The money would be paid out in annual $1 billion increments, according to the people, who asked not to be identified because the negotiations are private.J&J and the distributors -- which deliver the majority of prescription medications to U.S. pharmacies -- made the proposal in talks with a group of state attorneys general, the people said. The proposals came on the eve of the first federal trial in Cleveland over responsibility for the public-health crisis tied to opioids.Shares of J&J gained 2.2% at 10:38 a.m. in New York on Wednesday, while McKesson shares rose 7.4%, Cardinal rose 5.7% and AmerisourceBergen gained 6.4%.Teva Pharmaceutical Industries Ltd., another drug manufacturer targeted in the nationwide litigation, offered to give away more than $15 billion in generic drugs, including those that help fight opioid overdoses, to resolve all of its cases, said the people. That agreement would run over 10 years, the people said.Israel-based Teva’s shares rose 6.3% in New York on news of the settlement proposal. Teva’s bonds were among the top performers in the U.S. high-yield market on Wednesday, according to Trace bond trading data. The company’s 6% unsecured bonds rose more than 1.5 cents on the dollar to around 91.5.Other opioid manufacturers implicated in the federal trial, including Mallinckrodt and Endo, also rose in the wake of the news.If all the proposals are accepted, the Cleveland trial likely will be put off given that the three distributors and Teva are the main defendants, the people said. In the trial, two counties are seeking reimbursement for the hundreds of millions in tax dollars spent on the fallout from opioid addictions and overdoses.“As we’ve stated previously, we remain open to viable options to resolve these cases, including through settlement,” Ernie Knewitz, a J&J spokesman, said in an emailed statement.U.S.-based Teva spokeswoman Kelley Dougherty declined to comment on the proposed deal. AmerisourceBergen spokesman Gabriel Weissman and Brandi Martin, a Cardinal Health spokeswoman, also declined to comment. McKesson spokeswoman Sunny Rodriguez didn’t respond to requests for comment.Samantha Fisher, a spokeswoman for Tennessee Attorney Herbert Slatery III, didn’t respond to an emailed request for comment, sent after regular business hours. Slatery is one of the leaders of the negotiations.It’s the first time J&J has put serious money on the table to end its opioid liability, the people said. The drugmaker agreed earlier this month to pay $20.4 million to two Ohio counties to avoid a federal trial, but that didn’t extend to any other opioid claim. Some analysts have said it may take as much as $150 billion to resolve all the opioid cases on file.What Bloomberg Intelligence Says:Johnson & Johnson’s settlement of two opioid cases in Ohio, if reflective of a global settlement, is in-line with our expectation that it could pay up to $5 billion. The news, along with its lower-than-expected Oklahoma fine, may indicate J&J won’t have to contribute much more than others based on its ability to pay.\-- Sam Fazeli, senior pharmaceutical analystClick here to view the research“It’s very rare for J&J to do anything else other than litigate these kinds of cases to the bitter end,” said Carl Tobias, a University of Richmond law professor who teaches about mass torts. “I think investors are going to be very happy they are talking global settlement.”Tobias said an Oklahoma judge’s decision to hit J&J with $572 million in damages over its sales of opioid painkillers in that state may have sent J&J an unmistakable signal. That judge acknowledged Tuesday that he made a $107 million error in his damages ruling and cut the award to $420 million.“That ruling may have showed them that no matter where they try those cases, they are going to have trouble persuading judges and juries they shouldn’t be on the hook for the costs of the opioid crisis,” Tobias said.The distributors’ latest proposal is $8 billion higher than the $10 billion offer they made in August. The National Association of Attorneys General, the group sponsoring talks on behalf of more than 35 states, countered with a demand for $45 billion at the time.The drug distributors generate large amounts of cash that could be used to pay a settlement. In its 2019 fiscal year, San Francisco-based McKesson generated $4.04 billion from operations, according to data compiled by Bloomberg. In fiscal 2018, Cardinal brought in $2.77 billion and AmerisourceBergen $1.41 billion.QuickTake: The Opioid CrisisStates, cities and counties claim opioid makers, including J&J and Teva, downplayed the painkillers’ health risks and oversold their benefits through hyper-aggressive marketing campaigns. Distributors, considered to have the deeper pockets by plaintiffs’ lawyers, are accused of ignoring red flags about misuse of the painkillers and illegally flooding states with pills.For example, one pharmacy in Kermit, West Virginia -- population 400 -- received almost 5 million doses from McKesson between 2005 and 2006, records show. About 30 miles (50 kilometers) from Kermit, the company shipped more than 5.8 million doses to a pharmacy in Mount Gay -- population 1,800 -- between 2006 and 2014. Another 2.3 million doses went to a pharmacy three miles away.McKesson, Cardinal Health and AmerisourceBergen, along with other distributors, shipped a total of 76 billion pain pills over a six-year period starting in 2006, according to the U.S. Drug Enforcement Agency. The companies deny the governments’ allegations and have advanced dozens of legal and factual defenses, saying they complied with all state and federal laws.Teva has been grappling with billions in debt as well as thousands of opioid suits over its generic painkillers. Teva’s 2015 acquisition of Allergan Plc‘s generic business for $40.5 billion pushed the company’s debt load from $10 billion to $35 billion.Chief Executive Officer Kare Schultz, who stepped into his role in late 2017, is trying to right a company hurt by falling margins on generic drugs and rapidly declining sales in its best-selling Copaxone multiple-sclerosis drug. Last year, the drugmaker cut its net debt by almost $1 billion to $28.4 billion.Teva officials have told the attorneys generas’ lawyers that the company’s debt load leaves little free cash flow for an opioid settlement, the people said. That’s why it’s offering access to free Narcan, an overdose drug, the people said. In April, the U.S. Food and Drug Administration approved Teva’s request to start selling a generic version of Narcan, a nasal spray version of the opioid-overdose reversal agent Naxalone.In August, Teva officials set aside $646 million to help pay legal expenses related to its alleged role in the abuse of the addictive painkillers linked to tens of thousands American deaths annually. Those funds weren’t devoted to paying settlements.Teva’s bid to use the drugs-for-dismissal model to resolve its opioid liability may indicate the company could face bankruptcy if the proposal gets turned down, said Elizabeth Burch, a University of Georgia law professor who teaches about product-liability law.“I guess free drugs are better than nothing, but it’s not perfect,” Burch said in an interview. “The real question is whether the local governments want to keep this company out of bankruptcy by accepting this offer.”(Updates stock-price movements beginning in fourth paragraph)To contact the reporters on this story: Jef Feeley in Wilmington, Delaware at jfeeley@bloomberg.net;Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editors responsible for this story: David Glovin at dglovin@bloomberg.net, Timothy Annett, Mark SchoifetFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Zacks

    J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View

    J&J (JNJ) comes up with encouraging third-quarter 2019 results.

  • Lilly Gets FDA Approval for New Oral Tablets for Migraine
    Zacks

    Lilly Gets FDA Approval for New Oral Tablets for Migraine

    Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.

  • PR Newswire

    Lifshitz & Miller LLP Announces Investigation of Allegiant Travel Company, AMC Entertainment Holdings, Inc., Aqua Metals, Inc., CenturyLink, Inc., IVERIC bio, Inc., and Teva Pharmaceutical Industries Ltd.

    NEW YORK , Oct. 13, 2019 /PRNewswire/ -- Allegiant Travel Company (ALGT) Lifshitz & Miller announces investigation into possible securities laws in connection with a CBS News 60 Minutes segment criticizing ...

  • Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry
    Zacks

    Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry

    Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.

  • Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
    Zacks

    Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

    Teva Pharmaceutical Industries Ltd. (TEVA) closed at $6.98 in the latest trading session, marking a +0.14% move from the prior day.

  • Business Wire

    Teva to Host Conference Call to Discuss Third Quarter 2019 Financial Results at 8 a.m. ET on November 7, 2019

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its third quarter 2019 financial results on Thursday, November 7, 2019 at 7:00 a.m. ET. Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. A live webcast of the call will also be available on Teva's website at: http://ir.tevapharm.com.

  • AstraZeneca's Fasenra Gets FDA Nod for Self-Administration
    Zacks

    AstraZeneca's Fasenra Gets FDA Nod for Self-Administration

    The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study